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Abstract 
Background: The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification 
of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our 
aims were to analyze: (a) The associations of lysine, 2‑aminoadipic acid (2‑AAA) or pipecolic acid with the risk of T2D 
or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1‑year changes in these metabolites, and (c) 
whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D 
risk.
Methods: Two unstratified case‑cohort studies nested within the PREDIMED trial were used. For CVD analyses, we 
selected 696 non‑cases and 221 incident CVD cases; for T2D, we included 610 non‑cases and 243 type 2 diabetes 
incident cases. Metabolites were quantified using liquid chromatography–tandem mass spectrometry, at baseline and 
after 1‑year of intervention.
Results: In weighted Cox regression models, we found that baseline lysine  (HR+1 SD increase = 1.26; 95% CI 1.06–1.51) 
and 2‑AAA  (HR+1 SD increase = 1.28; 95% CI 1.05–1.55) were both associated with a higher risk of T2D, but not with CVD. 
A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with 
prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have 
a significant effect on 1‑year changes of the metabolites.
Conclusions: Our results provide an independent prospective replication of the association of 2‑AAA with future 
risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes‑dependent. No 
evidence of effects of MedDiet intervention on lysine, 2‑AAA or pipecolic acid changes was found.
Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003
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Background
Due to unhealthy diet and lifestyles in the context of 
ageing populations, the global epidemic of cardiovas-
cular disease (CVD) and type 2 diabetes (T2D) has 
reached unexpected dimensions. In order to stop this 
pandemic, it is of utmost importance to find robust 
biomarkers for both early detection and risk prediction 
of CVD [1] and T2D [2].
Previous studies have shown that circulating 2-ami-
noadipic acid (2-AAA) levels were associated with obe-
sity and metabolic syndrome [3, 4] and had the ability 
to predict the risk of future T2D [5]. The metabolite 
2-AAA results from the degradation pathway of lysine 
(Additional file  1: Fig.  S1), an essential amino acid. 
However, lysine has not been consistently associated 
with metabolic syndrome or T2D in previous studies 
[3]. In the pathway of lysine degradation (Additional 
file  1: Fig.  S1) there is also another metabolite, pipec-
olic acid, that may be implicated in other diseases such 
as human diabetic corneal stroma [6]. Thus, it seemed 
important to further explore lysine degradation path-
way in relation to T2D to find potential biomarkers 
and/or underlying biological mechanisms.
On the other hand, T2D and CVD share many com-
mon etiologic factors, and as explained above, 2-AAA 
has been postulated as a predictor factor for T2D [5]. 
Thus, it seems important to study the potential role of 
2-AAA in the development of CVD. In the same con-
text, lysine and 2-AAA have also been implicated in the 
development of other CVD risk factors, such as obesity 
and metabolic syndrome [3]. Consequently, the role 
of metabolites involved in lysine degradation (trough 
2-AAA) pathway should also be explored in association 
with CVD and whether the presence of T2D may mod-
ify this association should be studied.
One study suggested that 2-AAA may be modified by 
diet because a study reported significantly higher levels 
of 2-AAA after a beef meal compared to a baked her-
ring meal [7], proposing a potential dietary effect on 
the regulation of the pathway.
In the frame of the PREDIMED study, a large nutri-
tional intervention trial with Mediterranean diet (Med-
Diet) for the primary prevention of CVD, we assessed 
the following hypotheses: (a) baseline (or 1-year 
changes) in plasma levels of lysine, 2-AAA or pipec-
olic acid are associated with higher incidence of T2D 
and CVD; (b) the intervention with MedDiet induced 
changes in lysine, 2-AAA or pipecolic acid after 1-year; 
and (c) an intervention with MedDiet is able to attenu-
ate the potential adverse effects of lysine, 2-AAA or 
pipecolic acid on T2D or CVD risk.
Methods
To analyze the association of lysine, 2-AAA or pipecolic 
acid with CVD or T2D, we used two sets of case-cohort 
studies (Figs.  1, 2) nested within the PREDIMED trial 
(Trial registration: ISRCTN35739639; registration date: 
05/10/2005; recruitment start date 01/10/2003; http://
www.predi med.es). PREDIMED was a primary cardio-
vascular prevention trial testing Mediterranean diets, 
as described elsewhere [8, 9]. Briefly, 7447 participants 
(men aged 55–80  years and women aged 60–80  years), 
initially free of CVD but at high cardiovascular risk, were 
allocated to 3 dietary interventions: (1) a MedDiet sup-
plemented with extra-virgin olive oil (MedDiet + EVOO); 
(2) a MedDiet supplemented with mixed nuts (Med-
Diet + nuts); or (3) a control diet (low-fat diet). 
In the first nested case-cohort study (Fig. 1), cases were 
all primary CVD events with available blood samples 
and the subcohort was a random sample of all the trial. 
We included a random sample of ~ 10% of PREDIMED 
participants at baseline (the subcohort) and 233 inci-
dent cases of CVD with available blood samples which 
occurred during a median follow-up of 4.8  years (55 of 
the 288 incident cases of the PREDIMED trial had no 
available plasma samples). We also excluded 73 partici-
pants (63 non-cases and 10 cases) because of unavailable 
2-AAA or lysine metabolites data (Fig.  1). Finally, 917 
participants were included in our analysis: 221 incident 
cases and 730 participants in the subcohort (including 
34 overlapping cases). In addition, 809 participants (687 
participants in the subcohort and 147 cases, including 
25 overlapping cases) had available plasma samples after 
1-year of follow-up and were included in the analyses of 
metabolite changes at 1 year (Fig. 1).
In the design of the second case-cohort study (Fig.  2) 
we considered that 3541 participants did not have T2D 
at baseline in the full PREDIMED cohort and we only 
considered them for the second case-cohort design, as 
they were candidates to develop new-onset T2D. Among 
them, there were 273 incident cases of T2D observed 
during follow-up. The present study comprised a ran-
dom selection of 694 participants (approximately 20%) 
from the roster of all eligible subjects of the PRED-
IMED (subcohort), together with all incident cases of 
T2D with available plasma sample that occurred during 
a median follow-up of 3.8  years of intervention (cases). 
Baseline measurements for the metabolites were avail-
able for 610 non-cases and 243 incident cases (51 of the 
cases were overlapped with the subcohort). On the other 
hand, 669 participants, 516 non-cases and 153 (35 of 
them overlapped with the subcohort) cases that occurred 
after 1 year of follow-up, had available 1-year follow-up 
samples. Among them, 609 subjects had 1-year lysine, 
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2-AAA and pipecolic acid measurements and were finally 
included in the 1-year change analyses (Fig. 2).
The Research Ethics Committees for each of the 
recruitment centres approved the study protocol and all 
participants provided written informed consent.
Ascertainment of CVD and T2D cases
The primary endpoint of the PREDIMED trial was a 
composite outcome of non-fatal acute myocardial infarc-
tion, non-fatal stroke and cardiovascular death. Physi-
cians, blinded with respect to the intervention, reviewed 
yearly, in each recruitment center, all the participants’ 
medical charts to assess any incident CVD outcome. 
Other sources of information (also blinded with respect 
to the intervention), such as consultation of the National 
Death Index, were used to ascertain incident cases. Then, 
anonymized information was sent from each recruitment 
center to a blinded central Event Ascertainment Com-
mittee who finally adjudicated the events.
The PREDIMED protocol included T2D as a pre-spec-
ified secondary endpoint of the trial among participants 
initially free of diabetes. At baseline, prevalent T2D was 
identified by clinical diagnosis and/or use of antidiabetic 
medication. The diagnosis of incident T2D during follow-
up has been described elsewhere [9, 10] and followed 
the American Diabetes Association criteria [11]. Blinded 
study physicians collected information on the outcomes 
in the yearly ad hoc reviews of the participants’ medical 
charts. Also, information on incident cases of T2D was 
collected from continuous contact with participants and 
primary health care physicians, and annual follow-up vis-
its. Blinded to the intervention assignment, the Clinical 
End-Point Committee adjudicated the events according 
to standard criteria.
Covariate assessment
At baseline and at yearly follow-up visits, participants 
completed a questionnaire collecting lifestyle informa-
tion, educational achievement, history of illnesses, medi-
cation use, and family history of disease. Physical activity 
was assessed using the validated Spanish version of the 
Minnesota Leisure-Time Physical Activity questionnaire 
[12].
Original PREDIMED study:
Cohort: 7,447 participants (288 CVD incident cases)
Selected for nested study:
Total = 990 
Random 10% subcohort = 794  
(including 37 of the 233 incident cases) 
Non-cases = 757 
Plus all incident cases = 233
Participants included with metabolites measured at baseline:
Total = 917, Sub-cohort = 730
(including 34 of 221 incident cases)
Non-cases=696 
Cases=221
Participants included with metabolites measured at one year:
Total = 809, Sub-cohort = 687
(including 25 of 147 incident cases) 
Non-cases=662  //  Cases=147
63 Non-cases and 10 incident case without 2AAA 
measurement at baseline
55 incident cases without available plasma 
samples
108 not included in the 1-year change analysis:
37 incident cases within the first year of follow-up
64 non-cases without 2AAA measurement at year 1 
7 cases without 2AAA measurement at year 1 
Fig. 1 Flow‑chart of the case‑cohort design for CVD. CVD cardiovascular disease
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Study samples and metabolite profiling
Fasting blood samples were collected at baseline and after 
1  year of follow-up. After centrifugation, plasma EDTA 
was collected, and aliquots were coded and kept refriger-
ated until they were stored at − 80  °C. Pairs of samples 
(baseline and first-year visits from each participant) were 
randomly ordered and shipped on dry ice to the Broad 
Institute for the metabolomics analyses.
Liquid chromatography tandem mass spectrometry 
(LC–MS) was used to measure polar plasma metabolites. 
Negative ion mode, targeted MS analyses of 2-AAA were 
conducted as described previously [5]. Briefly, LC–MS 
samples were prepared from plasma (30 µL) via protein 
precipitation with the addition of four volumes of 80% 
methanol containing inosine-15N4, thymine-d4 and 
glycocholate-d4 internal standards (Cambridge Isotope 
Laboratories; Andover, MA). The samples were centri-
fuged (10 min, 9000×g, 4 °C) and the supernatants were 
analyzed using an ACQUITY UPLC (Waters, Milford 
MA) coupled to a 5500 QTRAP triple quadrupole mass 
spectrometer (AB SCIEX, Framingham, MA). Extracts 
(10 µL) were injected directly onto a 150 × 2.0 mm Luna 
NH2 column (Phenomenex; Torrance, CA). The column 
was eluted at a flow rate of 400 µL/min with initial condi-
tions of 10% mobile phase A (20 mM ammonium acetate 
and 20  mM ammonium hydroxide in water) and 90% 
mobile phase B (10 mM ammonium hydroxide in 75:25 
v/v acetonitrile/methanol) followed by a 10  min linear 
gradient to 100% mobile phase. MS data were acquired 
using multiple reaction monitoring scans tuned using 
authentic reference standards. The ion spray voltage 
was − 4.5  kV and the source temperature was 500  °C. 
Raw data were processed using MultiQuant 2.1 soft-
ware (SCIEX, Framingham MA). High resolution, posi-
tive ion mode analyses of lysine and pipecolic acid were 
conducted using a hydrophilic interaction liquid chro-
matography (HILIC) LC–MS method as described pre-
viously [13]. Briefly, data were acquired using a Nexera 
X2 U-HPLC system (Shimadzu Scientific Instruments; 
Marlborough, MA) coupled to a Q Exactive orbitrap 
mass spectrometer (Thermo Fisher Scientific; Waltham, 
MA). Metabolites were extracted from plasma (10 µL) 
using 90 µL of 74.9:24.9:0.2 v/v/v acetonitrile/methanol/
formic acid containing stable isotope-labeled internal 
standards (valine-d8, Isotec; and phenylalanine-d8, Cam-
bridge Isotope Laboratories; Andover, MA). The extracts 
Original PREDIMED study:
Cohort: 3,541 participants without T2D 
at baseline (273 T2D incident cases)
Selected for nested study:
Total = 892
Random 20% subcohort = 694 
(including 53 of the 251 incident cases)
Non-cases = 641
Plus all incident cases = 251
Participants included with metabolites measured at baseline:
Total = 853, Sub-cohort = 661
(including 51 of 243 incident cases)
Non-cases=610 
Cases=243
Participants included with metabolites measured at one year:
Total = 609, Sub-cohort = 495
(including 35 of 149 incident cases) 
Non-cases=460  // Cases=149
209 not included in the 1-year change analysis:
-140 Non-cases without available plasma 
samples or without lysine/2-AAA/pipecolic acid 
data
- 67 cases without available plasma samples or 
or without lysine/2-AAA/pipecolic acid data 
- 28 incident cases within the first year of follow-
up
22 incident cases without available plasma 
samples
33 Non-cases and 8 incident cases without 
lysine/2AAA measurement at baseline
Fig. 2 Flow‑chart of the case‑cohort design for T2D. T2D type 2 diabetes
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were centrifuged (10 min, 9000×g, 4 °C), and the super-
natants were injected onto a 150 × 2 mm Atlantis HILIC 
column (Waters; Milford, MA). The column was eluted 
isocratically at a flow rate of 250 µL/min with 5% mobile 
phase A (10  mM ammonium formate and 0.1% formic 
acid in water) for 1 min followed by a linear gradient to 
40% mobile phase B (acetonitrile with 0.1% formic acid) 
over 10  min. Polar metabolite MS analyses were car-
ried out using electrospray ionization in the positive ion 
mode using full scan analysis over m/z 70–800 at 70,000 
resolution and 3 Hz data acquisition rate. Additional MS 
settings were: ion spray voltage, 3.5 kV; capillary temper-
ature, 350  °C; probe heater temperature, 300  °C; sheath 
gas, 40; auxiliary gas, 15; and S-lens RF level 40. Raw data 
were processed using Progenesis QI software (NonLin-
ear Dynamics) for feature alignment, nontargeted signal 
detection, and signal integration. Compound identities 
were confirmed using reference standards and reference 
samples. Internal standard peak areas were monitored 
for quality control and to ensure system performance 
throughout analyses. Pooled plasma reference samples 
were analyzed at intervals of approximately 20 samples 
as an additional quality control and to determine ana-
lytical reproducibility [14]. Coefficients of variation (CV) 
for 2-AAA were 42.4% and 41.5% in the CVD (n = 126 
pooled samples) and T2D (n = 124 pooled samples) 
datasets, respectively. Lysine CVs were 6.8% and 1.9% 
and pipecolic acid CVs were 10.6% and 2.3% in the CVD 
(n = 100 pooled samples) and T2D (n = 92 pooled sam-
ples) datasets, respectively.
Statistical analysis
The analyses in both case-cohort studies were run in par-
allel and following the same scheme, so we will describe 
the common methods. Only small differences concerning 
adjustments for multivariable models were introduced 
and will be summarized below.
Baseline analyses
Baseline lysine, 2-AAA and pipecolic acid values were 
normalized and scaled in multiples of 1 SD with Blom’s 
inverse normal transformation [15]. We fitted weighted 
Cox regression models using Barlow weights to account 
for the over-representation of cases, as recommended 
for case-cohort designs [16]. We calculated hazard ratios 
(HR) and their 95% confidence intervals (95% CI) for 
CVD or T2D by quartiles of baseline lysine, 2-AAA or 
pipecolic acid. Quartile cut-off points were generated 
based on the distributions of each metabolite among sub-
cohort. We conducted tests of linear trend by examining 
an ordinal score based on the median value in each quar-
tile of lysine, 2-AAA or pipecolic acid in the multivari-
able models. Follow-up time was calculated from the date 
of enrollment to the date of diagnosis of CVD/T2D for 
cases, and to the date of the last visit or the end of the 
follow-up period for non-cases (December 1, 2010). Pro-
gressively further adjusted models were designed: first, a 
model adjusted for age, sex and intervention group was 
run; secondly, we included a multivariable adjustment 
including as covariates BMI (kg/m2), smoking (never/
current/former), leisure-time physical activity (metabolic 
equivalent task [MET]s-min/day), educational level (pri-
mary vs secondary or higher), hypertension and dyslipi-
demia for the association with T2D, and, also including 
baseline T2D and family history of CVD for the associa-
tion with CVD. An additional model was designed for the 
association with T2D including also the adjustment for 
plasma baseline glucose (both continuous and quadratic 
term included in the model).
In order to assess the potential relationship of this 
pathway and other factors underlying the development 
of T2D, the correlations (Pearson) between 2-AAA 
and baseline glucose, insulin, LDL-c and HDL-c were 
analyzed.
As an additional analysis, we wanted to observe the 
potential modifying role of prevalent T2D on the asso-
ciations between baseline lysine, 2-AAA or pipecolic 
acid with CVD. A new variable combining the baseline 
diabetic status and the levels of each metabolite (below/
above the median) was introduced into the models. 
Moreover, two independent models for diabetics and for 
non-diabetics were fitted.
To assess if the intervention with MedDiet was an 
effect modifier of the associations between baseline val-
ues of the metabolites and the risk of T2D or CVD, fully 
adjusted models for the case-cohorts of both CVD and 
T2D were fitted and multiplicative independent prod-
uct-terms were used to assess the potential interactions. 
Potential multiplicative interactions between the inter-
vention group (MedDiet + EVOO, MedDiet + nuts or 
control) and the dichotomous variable for lysine, 2-AAA 
and pipecolic acid (defined by the values below/above 
its respective median) were tested with the likelihood 
ratio test. Moreover, three new independent variables 
combining the intervention groups (MedDiet + EVOO, 
MedDiet + nuts, or control) and the dichotomous vari-
able defined for each metabolite by its median (below or 
above) were created and introduced separately in fully 
adjusted models to analyze the effects of each metabo-
lite stratified by intervention group. The reference cat-
egory was the group of subjects allocated to the control 
group of the trial and the group of participants below the 
median of each metabolite. Additionally, adjustment for 
propensity scores that used 30 baseline variables to esti-
mate the probability of assignment to each of the inter-
vention groups and robust variance estimators were used 
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to take into account that a small percentage of partici-
pants were non-individually randomized to the interven-
tion groups and minor imbalances in baseline covariates 
existed in the trial [9].
One‑year changes
To assess the associations between 1-year changes in 
lysine, 2-AAA and pipecolic acid and subsequent risk of 
CVD or T2D, only the cases that occurred after 1-year 
follow-up were used.
First of all, we calculated the changes between 1-year 
measurements and baseline for each metabolite and then 
normalized the differences using Blom’s inverse nor-
mal transformation. We used the same Cox regression 
models that for baseline analyses but including as inde-
pendent variable 1-year changes for each metabolite and 
adjusting for their respective baseline values.
We also assessed the combined effects of intervention 
and 1-year changes for the three metabolites and tested 
the interactions between intervention groups and 1-year 
changes. As we did at baseline, propensity scores adjust-
ment and robust variance estimators were used in these 
models.
To analyze the effects of intervention on metabolites 
changes, we only included participants in the selected 
subcohorts representing a random sample of the full 
roster of the trial (CVD and T2D cases not included in 
subcohorts were excluded). We used a linear regression 
model with the intervention as the main independent 
variable and 1-year changes in lysine, 2-AAA and pipec-
olic acid (residual change obtained after a regression of 
the 1-year metabolite value on baseline value), respec-
tively, as dependent variables and adjusted for the fol-
lowing independent covariates: age, sex, BMI, smoking, 
leisure-time physical activity, hypertension and dyslipi-
demia. Again, propensity scores adjustment and robust 
variance were used in these models.
Results
Baseline characteristics of participants, included in T2D 
and CVD case-cohort designs, are shown in Tables 1 and 
2 respectively. In the baseline comparison of characteris-
tics between incident T2D cases and non-cases, we found 
that baseline glucose levels among future diabetes cases 
pointed to a pre-diabetic baseline stage. In fact, according 
to the American Diabetes Association criteria for predia-
betes [17] considering only fasting glucose, the 47% of the 
subjects included in the subcohort appeared to present 
baseline prediabetes whereas the 86% of T2D incident 
cases presented prediabetes at baseline. On the other 
hand, subsequent incident CVD cases (as compared to 
non-cases) were at baseline older and more likely to be 
diabetic, sedentary and smokers.
Table 1 Baseline characteristics of the participants according to the case-cohort design for T2D
BMI body mass index, LTPA leisure time physical activity, MedDiet Mediterranean diet, CVD cardiovascular disease, EVOO extra-virgin olive oil
a Including 51 overlapping cases
Subcohort (n = 661)a T2D cases (n = 243)
Age (years) 66.5 (5.7) 66.4 (5.7)
BMI (kg/m2) 29.8 (3.6) 30.8 (3.4)
LTPA (METs‑min/day) 240 (241) 248 (233)
Total energy intake (kcal/day) 2279 (560) 2335 (620)
Adherence to MedDiet (14 items) 8.65 (1.91) 8.52 (1.82)
Sex, female (%) 61.7 54.7
Family history of CVD (%) 30.1 22.2
Education, secondary or higher (%) 25.3 23.5
Plasma baseline glucose (mg/dl) 100 (15) 117 (18)
Dyslipidaemia (%) 84.9 79.4
Hypertension (%) 90.8 95.9
Smoking
 Never (%) 60.2 53.1
 Current (%) 16.8 25.1
 Former (%) 23 21.8
Intervention group
 Control (%) 32.1 35.4
 MedDiet + EVOO (%) 30.4 30.5
 MedDiet + nuts (%) 37.5 34.2
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We present in parallel the results obtained for the T2D 
case-cohort and CVD case-cohort studies. In Table  3 
we show the association of baseline lysine, 2-AAA or 
pipecolic acid with CVD or T2D. We found that higher 
levels of lysine, 2-AAA and pipecolic acid were associ-
ated with T2D but the strongest association was found 
for 2-AAA, which was significantly associated with an 
increased risk of T2D in the basic model adjusted for sex, 
age and intervention group  (HR+1 SD increase = 1.29; 95% 
CI 1.10–1.52 Table 3), in the multivariable model  (HR+1 
SD increase = 1.27; 95% CI 1.07–1.50, data not shown) and 
even in the plasma glucose-adjusted model  (HR+1 SD 
increase = 1.28; 95% CI 1.05–1.55; Table  3). This associa-
tion was monotonic across increasing quartiles of 2-AAA 
(p for trend = 0.026). Similarly, we observed that higher 
levels of lysine were also associated with a higher risk of 
T2D in the fully adjusted model  (HR+1 SD increase = 1.26; 
95% CI 1.06–1.51; Table  3). When the three metabo-
lites were simultaneously included in the fully adjusted 
model the effects were attenuated but they were still evi-
dent for 2-AAA and lysine  (HR+1 SD increase 2-AAA  = 1.21; 
95% CI 0.99–1.47 and  HR+1 SD increase lysine = 1.20; 95% CI 
0.99–1.44; Table 3). To deepen into the role of the path-
way in the development of T2D, we analyzed the poten-
tial correlations between baseline 2-AAA and glucose, 
insulin, HDL-c and LDL-c for the T2D case-cohort. 
These correlations, though statistically significant, were 
not particularly high. The correlation between base-
line 2-AAA and fasting glucose was r = 0.161; p < 0.001 
(n = 904) and the correlation between baseline 2-AAA 
with insulin was r = 0.179; p < 0.001 (n = 713). In con-
trast, an inverse correlation was found between 2-AAA 
and HDL-c (r = − 0.134; p < 0.001; n = 757) and between 
2-AAA and LDL-c (r = − 0.116; p = 0.016; n = 742).
In the main analyses of the association of lysine, 
2-AAA and pipecolic acid with CVD we did not observe 
any significant result (Table 3). We additionally repeated 
these analyses considering the combined variable prev-
alent T2D and levels of each metabolite (Additional 
file  1: Fig.  S2), and we found the highest risk of CVD 
for subjects with both prevalent T2D at baseline and 
high levels of lysine at baseline. A significant interaction 
between lysine levels (below or above the median) and 
T2D at baseline (p = 0.032; Additional file 1: Fig. S2) was 
observed.
As a next step, we assessed if the dietary intervention 
with MedDiet was able to modify the effects of base-
line levels of lysine, 2-AAA and pipecolic acid on T2D 
and CVD risk. We did not find any significant interac-
tion for lysine, 2-AAA or pipecolic acid and the risk 
of T2D (Additional file  1: Fig.  S3). The modification 
effect of the intervention was evident for CVD risk: we 
found a significant multiplicative interaction between 
baseline levels of lysine and the intervention group (p 
Table 2 Baseline characteristics of the participants according to the case-cohort design for CVD
BMI body mass index, LTPA leisure time physical activity, MedDiet Mediterranean diet, CVD cardiovascular disease, EVOO extra-virgin olive oil
a Including 34 overlapping cases
Subcohort (n = 730)a CVD cases (n = 221)
Age (years) 67 (5.8) 69.5 (6.5)
BMI (kg/m2) 29.8 (3.6) 29.6 (3.8)
LTPA (METs‑min/day) 261 (258) 232 (235)
Total energy intake (kcal/day) 2330 (615) 2379 (687)
Adherence to MedDiet (14 items) 8.8 (1.93) 8.4 (1.81)
Sex, female (%) 56.9 39.8
Family history of CVD (%) 25.9 18.6
Diabetes prevalence (%) 47 65.2
Education, secondary or higher (%) 25 19
Dyslipidaemia (%) 74.4 57.9
Hypertension (%) 83.3 82.8
Smoking
 Never (%) 62.6 44.8
 Current (%) 12.5 19.5
 Former (%) 24.9 35.7
Intervention group
 Control (%) 29.6 36.7
 MedDiet + EVOO (%) 37.2 34.4
 MedDiet + nuts (%) 33.2 29
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interaction-2df = 0.031; Fig.  3), suggesting that subjects 
with low baseline levels of lysine and allocated to one of 
the MedDiet intervention groups may present the low-
est risk for CVD. Both baseline 2-AAA and pipecolic 
acid showed the same pattern of association for Med-
Diet + EVOO group but the interaction was not statisti-
cally significant for any of them.
Finally, we analyzed if 1-year changes in lysine, 
2-AAA and pipecolic acid were prospectively associated 
with T2D or CVD risk (Table  4). We found that 1-year 
increases in lysine, 2-AAA and pipecolic acid were not 
significantly associated with higher T2D risk  (HR+1 SD 
increase in lysine = 0.80; 95% CI 0.58 to 1.10;  HR+1 SD increase in 
2-AAA  = 1.29; 95% CI 0.98 to 1.70;  HR+1 SD increase in pipecolic 
acid = 1.18; 95% CI 0.88 to 1.58). One-year increases in 
lysine, 2-AAA or pipecolic acid were neither associated 
with the risk of CVD after 1-year of intervention  (HR+1 
SD increase in lysine = 0.99; 95% CI 0.80 to 1.24;  HR+1 SD increase 
in 2-AAA  = 0.81; 95% CI 0.63 to 1.04;  HR+1 SD increase in pipec-
olic acid = 1.10; 95% CI 0.87 to 1.37) (Table  4). When the 
potential effect modification by the intervention was 
considered (Additional file  1: Fig.  S4), we found no sig-
nificant multiplicative interaction for T2D. However, we 
found that MedDiet + EVOO appeared to be associated 
with a reduction in the risk of T2D especially among 
subjects who increased their levels of lysine (p = 0.004) 
and pipecolic acid (p = 0.041) after 1-year of interven-
tion compared to the reference group (subjects of the 
control group with 1-year changes below the median of 
each metabolite). For CVD, we did not find any pattern 
of association when stratifying by intervention group 
(Additional file 1: Fig. S5).
Table 3 Association [HR (95% CI)] between  baseline levels of  lysine, 2-aminoadipic acid and  pipecolic acid 
with cardiovascular disease or type 2 diabetes
CVD cardiovascular disease, T2D type 2 diabetes, MV mutivariable
a Adjusted for age, sex and intervention
b Basic model additionally adjusted for BMI, smoking, dyslipidemia, hypertension and baseline plasma glucose
c Basic model additionally adjusted for BMI, smoking, dyslipidemia, hypertension, T2D, family history of CVD
Q1 Q2 Q3 Q4 p linear trend 1 SD increase
Baseline lysine
 Outcome: T2D
  Basic  modela Ref. 1.10 (0.70–1.71) 1.47 (0.95–2.28) 1.24 (0.80–1.92) 0.189 1.11 (0.96–1.29)
  MV adjusted  modelb Ref. 1.19 (0.67–2.11) 1.56 (0.88–2.75) 1.66 (0.96–2.86) 0.038 1.26 (1.06–1.51)
  MV adjusted for 2‑AAA and pipec. Ref. 1.17 (0.67–2.07) 1.52 (0.85–2.70) 1.50 (0.87–2.60) 0.113 1.20 (0.99–1.44)
 Outcome: CVD
  Basic  modela Ref. 0.86 (0.55–1.34) 0.96 (0.61–1.51) 0.94 (0.60–1.47) 0.897 0.99 (0.81–1.20)
  MV adjusted  modelc Ref. 0.80 (0.48–1.29) 1.01 (0.62–1.65) 0.84 (0.51–1.38) 0.718 0.98 (0.82–1.17)
  MV adjusted for 2‑AAA and pipec. Ref. 0.78 (0.49–1.35) 0.99 (0.61–1.60) 0.82 (0.49–1.35) 0.636 0.98 (0.82–1.17)
Baseline 2‑AAA 
 Outcome: T2D
  Basic  modela Ref. 0.95 (0.59–1.54) 1.40 (0.89–2.21) 1.92 (1.23–1.54) 0.001 1.29 (1.10–1.52)
  MV adjusted  modelb Ref. 1.28 (0.66–2.50) 1.51 (0.82–2.77) 1.94 (1.03–3.63) 0.026 1.28 (1.05–1.55)
  MV adjusted for lysine and pipec. Ref. 1.32 (0.68–2.59) 1.43 (0.77–2.63) 1.81 (0.97–3.37) 0.050 1.21 (0.99–1.47)
 Outcome: CVD
  Basic  modela Ref. 1.11 (0.70–1.74) 0.94 (0.59–1.51) 1.21 (0.76–1.90) 0.532 1.06 (0.90–1.23)
  MV adjusted  modelc Ref. 1.18 (0.73–1.91) 0.84 (0.51–1.40) 1.13 (0.69–1.83) 0.894 1.00 (0.85–1.18)
  MV adjusted for lysine and pipec. Ref. 1.20 (0.74–1.95) 0.86 (0.51–1.43) 1.19 (0.71–1.99) 0.766 1.01 (0.85–1.20)
Baseline pipecolic acid
 Outcome: T2D
  Basic  modela Ref. 1.32 (0.86–2.02) 1.13 (0.72–1.78) 1.46 (0.93–2.31) 0.171 1.13 (0.96–1.32)
  MV adjusted  modelb Ref. 1.24 (0.72–2.14) 0.97 (0.55–1.71) 1.37 (0.78–2.41) 0.411 1.13 (0.92–1.13)
  MV adjusted for lysine and 2‑AAA Ref. 1.07 (0.62–1.87) 0.86 (0.49–1.51) 1.32 (0.74–2.36) 0.506 1.08 (0.88–1.32)
 Outcome: CVD
  Basic  modela Ref. 0.69 (0.44–1.09) 0.77 (0.49–1.21) 0.93 (0.61–1.42) 0.948 1.03 (0.88–1.20)
  MV adjusted  modelc Ref. 0.71 (0.45–1.11) 0.68 (0.42–1.11) 0.84 (0.55–1.38) 0.610 0.99 (0.83–1.18)
  MV adjusted for lysine and 2‑AAA Ref. 0.70 (0.43–1.14) 0.70 (0.43–1.14) 0.88 (0.55–1.41) 0.669 0.99 (0.82–1.20)
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Finally, we found that neither the intervention with 
MedDiet + EVOO nor with MedDiet + nuts were associ-
ated with statistically significant 1-year changes in lysine, 
2-AAA or pipecolic acid (Additional file 1: Table S1).
Discussion
In the frame of the PREDIMED trial we found that (1) 
baseline lysine and especially 2-AAA circulating lev-
els were associated with future risk of T2D but not 
with CVD risk; (2) a baseline diabetic status appeared 
to modify the association between baseline lysine levels 
and subsequent CVD risk so that only subjects who were 
diabetic at baseline exhibited an association between 
higher lysine levels and increased risk of future CVD; (3) 
1-year changes in lysine, 2-AAA and pipecolic acid were 
not associated with subsequent CVD or T2D risk; (4) the 
MedDiet did not show any significant effect on 1-year 
changes neither in 2-AAA nor in lysine; (5) the MedDiet 
supplemented with nuts or with EVOO may be reduc-
ing CVD or T2D risk through the regulation of different 
biological mechanisms than those related to lysine deg-
radation. However, MedDiet may be modifying the risk 
conferred by high levels of metabolites included in the 
lysine degradation pathway.
A previous work published by Wang et  al. [5], found 
in two independent cohorts—Framingham Heart Study 
(FHS)-Offspring Cohort and Malmö Diet and Cancer 
Study (MDC)-Cardiovascular Cohort-that high 2-AAA 
predicted the risk of developing T2D in normoglyce-
mic individuals. Our results confirmed this associa-
tion among subjects at high cardiovascular risk showing 
that the higher the baseline levels of 2-AAA, the higher 
the subsequent T2D risk in this Mediterranean popula-
tion. This is an important replication and update of the 
results considering that all PREDIMED participants ran-
domly selected for the T2D case-cohort were at high risk 
Fig. 3 Multivariate adjusted hazard ratios (HRs; 95% confidence intervals [CIs]) of incident cardiovascular disease for quartiles (Q) of baseline a 
lysine, b 2‑AAA and c pipecolic acid stratified by intervention group. p values are referred to the reference category composed of control group 
subjects with each baseline metabolite below the median
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of developing CVD and had baseline glucose levels that 
can be considered as a proxy of a pre-diabetic status. Our 
findings suggest that it seems possible to predict the risk 
of developing diabetes conferred by 2-AAA even at a 
pre-diabetic stage. We found similar results for the asso-
ciation of lysine with T2D but this association was not as 
robust as that for 2-AAA. A recent small cross sectional 
study reported that 2-AAA was also associated with 
obesity and metabolic syndrome in addition to T2D [3]. 
Consistent with our results, they also reported that lysine 
presented similar but weaker associations with these 
metabolic conditions. A mechanism potentially explain-
ing these associations may be that 2-AAA is elevated 
in response to high glucose levels, leading to increased 
insulin secretion and promoting mechanisms involved 
in maintaining glucose homeostasis in early stages of 
insulin resistance [5]. In the case of lysine, it may be ele-
vated at an early stage of this pathophysiological process 
to provide the 2-AAA substrate for a likely compensa-
tory mechanism [3]. In concordance with these explana-
tions, lysine was also found to be a predictor of insulin 
resistance and gestational diabetes during pregnancy in a 
previous study [18]. Moreover, both 2-AAA and pipecolic 
have been found to be elevated in diabetic corneas sug-
gesting that this pathway may be also related to diabetes-
induced diseases [6].
On the other hand, we observed no association 
between baseline lysine, 2-AAA or pipecolic acid levels 
and subsequent incidence of CVD in non-diabetic sub-
jects. However, the association of lysine with CVD was 
present in subjects with an initial diabetic status. There-
fore, it is likely that this association may only be appar-
ent among subjects with preexistent T2D. In this context, 
diabetic status may behave as an effect modifier of the 
association between lysine and CVD. The p value for 
the interaction test was statistically significant, support-
ing this interpretation. This finding represents a novelty 
and deserves future replication in further independ-
ent cohorts. It can be speculated that this effect modi-
fication by pre-existent diabetes may suggest that lysine 
can be implicated in the development of complications 
associated with T2D, because high levels of lysine may 
Table 4 Association [HR (95% CI)] between 1-year changes of  lysine, 2-aminoadipic acid and pipecolic acid with type 2 
diabetes and cardiovascular disease
CVD cardiovascular disease, T2D type 2 diabetes, MV multivariable, 2-AAA 2-aminoadipic acid
a Multivariable model adjusted for age, sex, intervention, BMI, smoking, dyslipidemia, hypertension, baseline plasma glucose and the respective baseline metabolite
b Multivariable model adjusted for age, sex, intervention, BMI, smoking, dyslipidemia, hypertension, T2D, family history of CVD and the respective baseline metabolite
Q1 Q2 Q3 Q4 p linear trend 1 SD increase 1 SD increase (adjusted 
for 1-year changes 
in 2-AAA and pipecolic 
acid)
1‑year change lysine
 Outcome: T2D
  MV adjusted  modelb Ref. 0.72 (0.37–1.40) 0.43 (0.17–1.07) 0.62 (0.29–1.34) 0.215 0.88 (0.65–1.20) 0.80 (0.58–1.10)
 Outcome: CVD
  MV adjusted  modela Ref. 1.07 (0.63–1.82) 0.93 (0.52–1.66) 0.93 (0.52–1.64) 0.796 0.95 (0.77–1.18) 0.99 (0.80–1.24)
Q1 Q2 Q3 Q4 p linear trend 1 SD increase 1 SD increase (adjusted 
for 1-year changes in 
lysine and pipecolic acid)
1‑year change 2‑AAA 
 Outcome: T2D
  MV adjusted  modelb Ref. 1.30 (0.63–2.67) 0.95(0.38–2.36) 1.66 (0.82–3.39) 0.214 1.23 (0–96–1.58) 1.29 (0.98–1.70)
 Outcome: CVD
  MV adjusted  modela Ref. 0.94 (0.52–1.69) 0.97 (0.55–1.72) 0.66 (0.35–1.21) 0.210 0.84 (0.67–1.05) 0.81 (0.63–1.04)
Q1 Q2 Q3 Q4 p linear trend 1 SD increase 1 SD increase (adjusted 
for 1-year changes in 
lysine and 2-AAA)
1‑year change pipecolic acid
 Outcome: T2D
  MV adjusted  modelb Ref. 1.45 (0.54–3.84) 1.22 (0.43–3.46) 1.42 (0.54–3.71) 0.483 1.08 (0.81–1.44) 1.18 (0.88–1.58)
 Outcome: CVD
  MV adjusted  modela Ref. 0.49 (0.21–1.12) 0.52 (0.24–1.13) 0.93 (0.47–1.84) 0.593 1.03 (0.83–1.28) 1.10 (0.87–1.37)
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represent a biomarker of a poorer control of glycemic 
levels in T2D. This interpretation should be taken with 
caution and further confirmation is needed.
In addition to the 2-AAA pathway of lysine degrada-
tion, L-homoarginine may be also synthesized from 
lysine catabolism and, this alternative pathway, involv-
ing arginine and nitric oxide synthesis [19, 20], may be 
related to CVD and T2D, as we have previously reported 
[21, 22].
Regarding the effect of the dietary intervention, we 
observed no effect of MedDiet on lysine, 2-AAA or 
pipecolic acid 1-year changes. Additionally, we did not 
find any significant multiplicative interaction between 
the MedDiet intervention and 1  year changes in lysine, 
2-AAA or pipecolic acid. However, we found that Med-
Diet may be modifying the effects of baseline lysine on 
CVD risk as we found a significant interaction between 
lysine and the intervention. In the same direction, results 
on 2-AAA and pipecolic acid pointed at the same effect 
of MedDiet + EVOO (non significant interaction). These 
results may be suggesting that although there is no a 
direct effect of diet on the levels of the metabolites, it 
is possible that MedDiet may be modifying the effects 
of metabolites on CVD or T2D risk by affecting other 
mechanisms that may involve different metabolic path-
ways, inflammation or oxidation. Further studies are 
needed to clarify the effect of diet on lysine, 2-AAA and 
pipecolic acid levels and the potential effect modification 
by dietary interventions on the CVD/T2D risk associated 
with these metabolites.
Our study presents some limitations. First, we do not 
have available data on glycated hemoglobin (HbA1c), 
which was previously reported to be a biomarker of dia-
betes and CVD damage, independently of fasting glucose 
[23]. Thus, new studies are needed to evaluate if lysine 
pathway metabolites may add value to the prediction 
of risk provided by HbA1c. Moreover, we did not find 
an effect of MedDiet on 1  year-changes in none of the 
studied metabolites. It may be possible that 1 year is not 
enough time to observe sound changes in metabolites, 
and as a consequence we did neither observe an associa-
tion between 1-year changes of metabolites and the sub-
sequent risk of T2D or CVD. Another limitation is that 
our results may be not generalizable because we used a 
Mediterranean population at high CVD risk. In addition, 
we cannot exclude the possibility of residual confounding 
regarding the observational associations between metab-
olites and cardiometabolic outcomes.
Consequently, these results, especially those suggesting 
a potential interaction between the nutritional interven-
tion and these 2 metabolites deserve further confirma-
tion in independent prospective cohort studies and trials 
[24]. However, our study presents important strengths: 
we used the case‐cohort design, which retains randomi-
zation, to both evaluate associations of 2-AAA and lysine 
with incident T2D and CVD. Our analyses were adjusted 
for multiple confounders within a well-characterized 
trial and, as an important novelty, we used repeated 
measurements of these metabolites, that allowed us 
to assess 2-AAA and lysine changes due to the dietary 
intervention.
Conclusions
In conclusion, our results provide an interesting inde-
pendent replication of the association of 2-AAA with 
future risk of T2D, a similar association for lysine and 
pipecolic acid and a suggestion of a diabetes-dependent 
association of lysine with subsequent CVD risk.
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